HDL metabolism and the role of HDL in the treatment of high-risk patients with cardiovascular disease

被引:36
作者
Brewer Jr. H.B. [1 ]
机构
[1] Department of Lipoprotein and Atherosclerosis Research, Cardiovascular Research Institute, Washington Hospital Center, Washington, DC 20010
关键词
Atorvastatin; Cholesteryl Ester Transfer Protein; Cholesterol Efflux; Acute Coronary Syndrome Patient; Torcetrapib;
D O I
10.1007/BF02938393
中图分类号
学科分类号
摘要
Developing new therapeutic approaches to treating residual cardiovascular risk of recurrent clinical events in statin-treated patients has been a major challenge for the cardiovascular field. Data from epidemiological evidence, animal models, and initial clinical trials indicate that increasing high-density lipoprotein (HDL) may be an effective new target for treating residual cardiovascular risk. Over the past several years, major advances have occurred in our understanding of HDL metabolism and of the important roles of the ABCA1 and ABCG1 transporters as well as the SR-BI receptor in cholesterol transport. Current approaches to HDL therapy include acute HDL infusion therapy in acute coronary syndrome patients and chronic oral HDL therapy in stable patients with cardiovascular disease. Definitive clinical trials will now be required to establish the safety and efficacy of increasing HDL in the treatment of patients with cardiovascular disease. Copyright © 2007 by Current Medicine Group LLC.
引用
收藏
页码:486 / 492
页数:6
相关论文
共 71 条
[1]  
Castelli W.P., Anderson K., Wilson P.W., Levy D., Lipids and risk of coronary heart disease: The Framingham Study, Ann Epidemiol, 2, pp. 23-28, (1992)
[2]  
Gordon D.J., Rifkind B.M., High-density lipoprotein: The clinical implications of recent studies, N Engl J Med, 321, pp. 1311-1316, (1989)
[3]  
Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S), Lancet, 344, pp. 1383-1389, (1994)
[4]  
Shepherd J., Cobbe S.M., Ford I., Et al., Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia, N Engl J Med, 333, pp. 1350-1351, (1995)
[5]  
Sacks F.M., Pfeffer M.A., Moye L.A., Et al., The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels, N Engl J Med, 335, pp. 1001-1009, (1996)
[6]  
Downs J.R., Clearfield M., Weis S., Et al., Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study, JAMA, 279, pp. 1615-1622, (1998)
[7]  
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo-controlled trial, Lancet, 360, pp. 7-22, (2002)
[8]  
Genest Jr J.J., Bard J.M., Fruchart J.C., Et al., Familial hypoalphalipoproteinemia in premature coronary artery disease, Arterioscler Thromb, 13, pp. 1728-1737, (1993)
[9]  
Badimon J.J., Badimon L., Fuster V., Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit, J Clin Invest, 85, pp. 1234-1241, (1990)
[10]  
Rubin E.M., Krauss R.M., Spangler E.A., Et al., Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI, Nature, 353, pp. 265-267, (1991)